Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

GeneDx Holdings (WGS) Shares Issued (2020 - 2026)

GeneDx Holdings has reported Shares Issued over the past 7 years, most recently at $58000.0 for Q1 2026.

Quarterly Shares Issued fell 99.58% to $58000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $32.9 million through Mar 2026, down 45.55% year-over-year, with the annual reading at $46.7 million for FY2025, 0.45% changed from the prior year.
Shares Issued was $58000.0 for Q1 2026 at GeneDx Holdings, down from $45.7 million in the prior quarter.
Over five years, Shares Issued peaked at $197.0 million in Q2 2022 and troughed at -$195.5 million in Q3 2022.
The 5-year median for Shares Issued is $256500.0 (2023), against an average of $9.7 million.
The largest YoY upside for Shares Issued was 57791.67% in 2025 against a maximum downside of 52533.33% in 2025.
A 5-year view of Shares Issued shows it stood at $195.4 million in 2022, then plummeted by 173.17% to -$143.0 million in 2023, then soared by 132.34% to $46.2 million in 2024, then dropped by 1.14% to $45.7 million in 2025, then crashed by 99.87% to $58000.0 in 2026.
Per Business Quant, the three most recent readings for WGS's Shares Issued are $58000.0 (Q1 2026), $45.7 million (Q4 2025), and -$280000.0 (Q3 2025).